News from us and our partners

Tags

Topics

0 results

News
26 March, 2024
Asceneuron joins critical path for Alzheimer’s Disease Consortium
News
21 March, 2024
Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease
News
20 March, 2024
Cure51 raises a €15 million seed round to harness the natural power of cancer survivors to develop first in class treatments and transform cancer into a curable disease
News
19 March, 2024
Moon Surgical's Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated
News
19 March, 2024
Mainstay Medical announces publication of the first neuromodulation study for low back pain with 5-year follow-up
News
18 March, 2024
Biotalys and Novonesis announce manufacturing and commercialisation partnership for EVOCA NG
News
18 March, 2024
Inventiva reports positive Phase 2 data for lanifibranor in MASH
News
14 March, 2024
Sofinnova Partners portfolio company Amolyt Pharma to be acquired by AstraZeneca
News
14 March, 2024
Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca
News
14 March, 2024
Elicit Plant announces its upcoming US biosolution launch with demonstrated 20% reduction of water consumption in broad acre crops
News
14 March, 2024
Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
News
12 March, 2024
Mainstay Medical publishes ReActiv8 age comparison data
News
11 March, 2024
Sensorion announces it has met primary endpoint for SENS-401 Phase 2a Clinical Study for residual hearing preservation
News
7 March, 2024
Inventiva resumes screening in Phase 3 trial of lanifibranor
News
7 March, 2024
NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s disease phase Ib/IIa trial
News
7 March, 2024
Signature of a partnership agreement with Kiro

Asceneuron joins critical path for Alzheimer’s Disease Consortium

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors to develop first in class treatments and transform cancer into a curable disease

Moon Surgical's Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated

Mainstay Medical announces publication of the first neuromodulation study for low back pain with 5-year follow-up

Biotalys and Novonesis announce manufacturing and commercialisation partnership for EVOCA NG

Inventiva reports positive Phase 2 data for lanifibranor in MASH

Sofinnova Partners portfolio company Amolyt Pharma to be acquired by AstraZeneca

Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca

Elicit Plant announces its upcoming US biosolution launch with demonstrated 20% reduction of water consumption in broad acre crops

Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy

Mainstay Medical publishes ReActiv8 age comparison data

Sensorion announces it has met primary endpoint for SENS-401 Phase 2a Clinical Study for residual hearing preservation

Inventiva resumes screening in Phase 3 trial of lanifibranor

NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s disease phase Ib/IIa trial

Signature of a partnership agreement with Kiro